US4029764A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hepatitis A antigen
Assignee: Merck and Co Inc
•
Filing: 1974-12-09
•
Granted: 1977-06-14
•
Expires: 1994-12-09
Abstract
Abstract Hepatitis A antigen obtained from the livers of non-human primates infected with hepatitis A (infectious hepatitis) virus has been found to be usable in fast, simple assays for hepatitis A antibody and thus usable in diagnosis of hepatitis A disease in humans, and for the preparation of hepatitis A vaccine.
Inventors
- 👤 Philip J. Provost
- 👤 Oswald L. Ittensohn
- 👤 Maurice R. Hilleman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 01:52
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/576; G01N33/5768; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
58 words
A composition consisting essentially of a physiological saline solution buffered at from about pH 6.0 to about pH 7.8 containing hepatitis A antigen having a buoyant density in CsCl of from about 1.32 g/cm 3 to about 1.36 g/cm 3 in concentration effective to give a measurable reaction with hepatitis A antibody in an immune adherence serological assay.
Claim 2
Dependent Claim
58 words
A composition consisting essentially of a physiological saline solution buffered at from about pH 6.0 to about pH 7.8 containing hepatitis A antigen having a buoyant density in CsCl of from about 1.32 g/cm 3 to about 1.36 g/cm 3 in concentration effective to give a measurable reaction with hepatitis A antibody in an immune adherence serological assay.
Claim 3
Dependent Claim
19 words
A composition according to claim 1 wherein the buffer is phosphate buffered saline and the pH is about 7.2.
Claim 4
Dependent Claim
15 words
A composition according to claim 1 wherein the hepatitis A antigen is inactivated or attenuated.
Claim 5
Dependent Claim
24 words
A method of preparing a vaccine to prevent hepatitis A disease comprising inactivating or attenuating the antigen contained in the composition of claim 1.
Claim 6
Dependent Claim
15 words
A method according to claim 4 wherein the inactivation or attenuation is effected by formalin.
Claim 7
Dependent Claim
61 words
A vaccine to prevent hepatitis A disease consisting essentially of a physiological saline solution buffered at from about pH 6.0 to about pH 7.8 containing inactivated or attenuated hepatitis A antigen in quantity effective to induce immunity to hepatitis A virus, the antigen having a buoyant density in CsCl of from about 1.32 g/cm 3 to about 1.36 g/cm 3 .
Claim 8
Dependent Claim
61 words
A vaccine to prevent hepatitis A disease consisting essentially of a physiological saline solution buffered at from about pH 6.0 to about pH 7.8 containing inactivated or attenuated hepatitis A antigen in quantity effective to induce immunity to hepatitis A virus, the antigen having a buoyant density in CsCl of from about 1.32 g/cm 3 to about 1.36 g/cm 3 .
Claim 9
Dependent Claim
24 words
A method of preventing hepatitis A disease in a susceptible mammalian species comprising administering an effective amount of a vaccine according to claim 6.
Claim 10
Dependent Claim
15 words
A vaccine according to claim 6 wherein the physiological saline solution is phosphate buffered saline.
Claim 11
Dependent Claim
24 words
A method of preventing hepatitis A disease in a susceptible mammilian species comprising administering an effective amount of a vaccine according to claim 8.
Claim 12
Dependent Claim
54 words
A vaccine against hepatitis A consisting essentially of inactivated or attenuated hepatitis A antigen of a particle size of 27 mμ and a buoyant density in CsCl of from about 1.32 g/cm 3 to about 1.36 g/cm 3 and being in an amount sufficient to induce formation of antibodies, and a physiologically acceptable medium.
Claim 13
Dependent Claim
54 words
A vaccine against hepatitis A consisting essentially of inactivated or attenuated hepatitis A antigen of a particle size of 27 mμ and a buoyant density in CsCl of from about 1.32 g/cm 3 to about 1.36 g/cm 3 and being in an amount sufficient to induce formation of antibodies, and a physiologically acceptable medium.
Claim 14
Dependent Claim
13 words
A vaccine according to claim 10 wherein the medium is phosphate buffered saline.
Claim 15
Dependent Claim
24 words
A method of preventing hepatitis A disease in a susceptible mammalian species comprising administering an effective amount of a vaccine according to claim 10.
Claim 16
Dependent Claim
37 words
A composition consisting essentially of hepatitis A antigen of a particle size of 27 mμ and a buoyant density in CsCl of from about 1.32 g/cm 3 to about 1.36 g/cm 3 and a physiologically acceptable medium.
Claim 17
Dependent Claim
37 words
A composition consisting essentially of hepatitis A antigen of a particle size of 27 mμ and a buoyant density in CsCl of from about 1.32 g/cm 3 to about 1.36 g/cm 3 and a physiologically acceptable medium.
Claim 18
Dependent Claim
13 words
A composition according to claim 13 wherein the medium is phosphate buffered saline.
Claim 19
Dependent Claim
15 words
A composition according to claim 13 wherein the hepatitis A antigen is inactivated or attenuated.
Claim 20
Dependent Claim
24 words
A method of preparing a vaccine to prevent hepatitis A disease comprising inactivating or attenuating the antigen contained in the composition of claim 13.
Claim 21
Dependent Claim
15 words
A method according to claim 16 wherein the inactivation or attenuation is effected by formalin.
Claim 22
Dependent Claim
33 words
A composition consisting essentially of hepatitis A antigen and a physiologically acceptable medium, the antigen having a buoyant density in CsCl of from about 1.32 g/cm 3 to about 1.36 g/cm 3 .
Claim 23
Dependent Claim
33 words
A composition consisting essentially of hepatitis A antigen and a physiologically acceptable medium, the antigen having a buoyant density in CsCl of from about 1.32 g/cm 3 to about 1.36 g/cm 3 .
Claim 24
Dependent Claim
13 words
A composition according to claim 18 wherein the medium is phosphate buffered saline.
Claim 25
Dependent Claim
14 words
A composition according to claim 18 wherein the hepatitis A is inactivated or attenuated.
Claim 26
Dependent Claim
24 words
A method of preparing a vaccine to prevent hepatitis A disease comprising inactivating or attenuating the antigen contained in the composition of claim 18.
Claim 27
Dependent Claim
15 words
A method according to claim 21 wherein the inactivation or attenuation is effected by formalin.
References Cited (Backward Citations)
US3636191A
Cited
US3735004A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-06-13 | 1980-12-13 | 1981-06-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-06-13 | 1984-12-13 | 1985-06-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-06-13 | 1988-12-13 | 1989-06-14 | $7700.00 | Window Closed / Lapsed |